Syros Pharmaceuticals, Inc.
NASDAQ:SYRS
1.98 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 9.936 | 14.88 | 23.488 | 15.093 | 1.982 | 2.05 | 1.101 | 0.317 | 0.317 | 0 | 0 |
| Cost of Revenue
| 2.252 | 2.967 | 0 | 0 | 0 | 0 | 1.527 | 0 | 0.602 | 0 | 0 |
| Gross Profit
| 7.684 | 11.913 | 23.488 | 15.093 | 1.982 | 2.05 | -0.426 | 0.317 | -0.285 | 0 | 0 |
| Gross Profit Ratio
| 0.773 | 0.801 | 1 | 1 | 1 | 1 | -0.387 | 1 | -0.899 | 0 | 0 |
| Reseach & Development Expenses
| 105.901 | 111.944 | 99.872 | 76.065 | 58.245 | 50.182 | 41.896 | 37.817 | 24.408 | 10.923 | 6.266 |
| General & Administrative Expenses
| 28.282 | 29.299 | 23.036 | 21.325 | 21.478 | 16.164 | 13.891 | 10.463 | 5.729 | 2.512 | 2.367 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 28.282 | 29.299 | 23.036 | 21.325 | 21.478 | 16.164 | 13.891 | 10.463 | 5.729 | 2.512 | 2.367 |
| Other Expenses
| 2.489 | -9.51 | 0 | 0 | 2.303 | 2.017 | 0.676 | 0.22 | 0.002 | 0.004 | 0 |
| Operating Expenses
| 134.183 | 141.243 | 122.908 | 97.39 | 79.723 | 66.346 | 55.787 | 48.28 | 30.137 | 13.435 | 8.665 |
| Operating Income
| -126.499 | -135.873 | -99.42 | -82.297 | -77.741 | -64.296 | -54.686 | -47.963 | -29.82 | -13.435 | -8.633 |
| Operating Income Ratio
| -12.731 | -9.131 | -4.233 | -5.453 | -39.224 | -31.364 | -49.669 | -151.303 | -94.069 | 0 | 0 |
| Total Other Income Expenses Net
| -38.075 | 41.219 | 12.862 | -1.741 | 2.303 | 2.017 | 0.676 | 0.22 | 0.002 | 0.004 | -0.032 |
| Income Before Tax
| -164.574 | -94.654 | -86.558 | -84.038 | -75.438 | -62.279 | -54.01 | -47.743 | -29.818 | -13.431 | -8.665 |
| Income Before Tax Ratio
| -16.563 | -6.361 | -3.685 | -5.568 | -38.062 | -30.38 | -49.055 | -150.609 | -94.063 | 0 | 0 |
| Income Tax Expense
| 2.084 | -45.353 | 3.907 | 1.792 | 2.55 | 2.017 | -1.527 | 0 | 0 | 0 | 0.594 |
| Net Income
| -164.574 | -49.301 | -90.465 | -85.83 | -75.438 | -62.279 | -54.01 | -47.743 | -29.818 | -13.431 | -9.259 |
| Net Income Ratio
| -16.563 | -3.313 | -3.852 | -5.687 | -38.062 | -30.38 | -49.055 | -150.609 | -94.063 | 0 | 0 |
| EPS
| -5.81 | -3.9 | -14.47 | -18.64 | -18.76 | -19.07 | -21.26 | -37.6 | -120.45 | -54.25 | -84.47 |
| EPS Diluted
| -5.81 | -3.9 | -14.47 | -18.64 | -18.76 | -19.07 | -21.26 | -37.6 | -120.45 | -54.25 | -84.47 |
| EBITDA
| -124.247 | -130.774 | -96.315 | -78.836 | -75.019 | -62.692 | -54.686 | -46.69 | -29.218 | -13.177 | -8.463 |
| EBITDA Ratio
| -12.505 | -8.789 | -4.101 | -5.223 | -37.85 | -30.581 | -49.669 | -147.287 | -92.17 | 0 | 0 |